Journal
LEUKEMIA RESEARCH
Volume 34, Issue 3, Pages 301-306Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2009.07.032
Keywords
LPL expression; LPL catalytical activity; IGHV mutational status; IGHV3 21 usage; Chronic lymphocytic leukemia; Prognosis
Categories
Funding
- Swedish Cancer Society
- Swedish Research Council
- Medical Faculty of Uppsala University
- Uppsala University Hospital
- Lion's Cancer Research Foundation in Uppsala, Sweden
Ask authors/readers for more resources
Lipoprotein lipase (LPL) expression has been shown to correlate with IGHV mutational status and to predict outcome in chronic lymphocytic leukemia (CLL). We here investigated the prognostic impact of LPL expression in relation to other prognostic markers including IGHV3-21 usage in 140 CLL patients. Additionally, we studied the catalytic activity of LPL in CLL cells. A significant difference in LPL mRNA expression was detected in IGHV unmutated compared to mutated CLL patients (p < 0.001). However, the poor-prognostic mutated/stereotyped IGHV3-21 patients did not differ from other mutated CLL cases. Clinical outcome was significantly different in CLL cases with high versus low LPL expression (p < 0.001), and LPL expression exceeded mutation status/IGHV3-21 usage as an independent prognostic marker. Finally, LPL protein expression correlated significantly with mRNA expression and was higher in IGHV unmutated versus mutated CLL (p = 0.018), although the majority of synthesized protein was catalytically inactive indicating a non-catalytical function in CLL. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available